Gelonhui March 14 丨 Jiuzhou Pharmaceutical (603456.SH) announced that on March 13, 2023, Hongzhou Investment, a wholly-owned subsidiary of the company, and Ningbo Jundu Private Equity Fund Management Co., Ltd. (“Kundu Management”), Ningbo Jiefeng Hongming Venture Capital Partnership (Limited Partnership) (known as “Jiefeng Investment”), Huang Xiqiang, Zhang Ning, Gan Quan and Huang Yong signed the “Ningbo Jundu Jingming Venture Capital Partnership (Limited Partnership)” to jointly invest in Ningbo Jundu Jingming Venture Capital Partnership (Limited Partnership). The total investment pledged by the partnership is RMB 55.1 million (including this investment), and Hongzhou Investment will use its own capital as a limited partner to pledge a capital of RMB 15 million, accounting for 27.22% of the total investment pledged by the partnership.

The partnership invests exclusively in the shares of the unlisted company Xihua Testing. Xihua Testing is a company that provides high-quality and efficient integrated services from proprietary drug development to approval for listing to global pharmaceutical companies.